BioRestorative Therapies Inc. (BRTX), a clinical-stage regenerative medicine company developing stem cell-based therapies and products, is scheduled to host a conference call at 10:30 am EST today to provide a clinical pipeline update.
The company's lead drug candidate is BRTX-100, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. BRTX-100 is being tested in a phase II trial in patients with chronic lumbar disc disease.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com